Arctic TherapeuticsIceland’s Arctic Therapeutics has secured €26.5m in a Series A financing aimed to push its oral drug candidates AT-O01 and AT-004 into clinical trails in patients with rare amyloid aggregation diseases including Alzheimer’s disease.
ADVERTISEMENT
Iceland’s Arctic Therapeutics has secured €26.5m in a Series A financing aimed to push its oral drug candidates AT-O01 and AT-004 into clinical trails in patients with rare amyloid aggregation diseases including Alzheimer’s disease.